Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03829501
What this trial is testing

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Who this might be right for
Squamous Cell Carcinoma of Head and NeckNon-small Cell Lung CancerHepatocellular Carcinoma+9 more
Kymab Limited 222
Not applicableLooking for participantsNCT06476119
What this trial is testing

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Who this might be right for
Breast Cancer Stage ITriple Negative Breast Cancer (TNBC)
The Netherlands Cancer Institute 490
Early research (Phase 1)Ended earlyNCT05035407
What this trial is testing

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Who this might be right for
Kita-kyushu Lung Cancer Antigen 1, Human
National Cancer Institute (NCI) 36
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)WithdrawnNCT04149444
What this trial is testing

Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Triple Negative Breast Cancer
AHS Cancer Control Alberta
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07786428
What this trial is testing

Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
University of Texas Southwestern Medical Center 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06519370
What this trial is testing

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 350
Post-approval studies (Phase 4)Looking for participantsNCT04790305
What this trial is testing

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Who this might be right for
Carcinoma BreastTriple-negative Breast CancerInvasive Ductal Carcinoma, Breast
Fudan University 1,072
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Early research (Phase 1)Ended earlyNCT02358200
What this trial is testing

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Who this might be right for
Triple Negative Metastatic Breast CancerBRCA-mutated Solid Tumor
Pamela Munster 23
Testing effectiveness (Phase 2)UnknownNCT05556200
What this trial is testing

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Who this might be right for
Breast CancerTriple-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 58
Not applicableActive Not RecruitingNCT07821229
What this trial is testing

Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)BRCA 1 Gene MutationBRCA 2 Gene Mutation
N.N. Petrov National Medical Research Center of Oncology 30
Early research (Phase 1)Study completedNCT03071757
What this trial is testing

The Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 139
Not applicableStudy completedNCT03539965
What this trial is testing

Triple-negative Breast Cancer: a New Perspective on Biomarkers

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast Cancer
Instituto Nacional de Cancer, Brazil 239
Testing effectiveness (Phase 2)Ended earlyNCT03729596
What this trial is testing

MGC018 With or Without MGA012 in Advanced Solid Tumors

Who this might be right for
Squamous Cell Carcinoma of Head and NeckTriple Negative Breast CancerMelanoma+3 more
MacroGenics 143
Early research (Phase 1)Active Not RecruitingNCT03821935
What this trial is testing

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 364
Not applicableStudy completedNCT03719833
What this trial is testing

Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents

Who this might be right for
Breast CancerSentinel Lymph Node BiopsyNeoadjuvant Chemotherapy
Clinical Hospital Center Rijeka 230
Testing effectiveness (Phase 2)Study completedNCT03333915
What this trial is testing

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Who this might be right for
Advanced High-grade Ovarian CancerTriple Negative Breast Cancer
BeiGene 128
Not applicableActive Not RecruitingNCT05309655
What this trial is testing

Cardiac Outcomes With Near-Complete Estrogen Deprivation

Who this might be right for
Breast CancerTriple Negative Breast CancerCardiovascular Complications
Duke University 90
Next Page